Markets
Borrow
Earn
Invest
Private
Security
Newsroom
More
Log In
Sign Up
Markets
Market Overview
Indices and commodities.
Digital Credit
Bitcoin treasury preferreds.
AI Stocks
The artificial intelligence theme.
Bitcoin Treasuries
Companies holding bitcoin.
Economy
Sectors, global markets and rates.
Popular Portfolios
13F filings, smart money.
Borrow
Borrow
Borrow USDT or USDC against your BTC without giving it up.
ReFi
Switch your bitcoin-backed loan and pay less interest.
Earn
Carry Trade
Borrow, invest, keep the spread.
Stock Dividends
Dividends from tokenized equities.
Invest
Private
Security
Newsroom
More
Company
About Us
Our leadership team, mission, and investors.
Whitepaper
Vision, purpose, and architecture behind Roxom.
Legal
Terms, privacy, and disclosures.
Resources
Help Center
Guides, FAQs & support.
Rulebook
Trading logic, platform rules, and fundamentals.
API Docs
Connect, authenticate, and build with our API.
Status
Current platform health and incidents.
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
1 BTC
=
- USD
BTC
SATS
Loading market data...
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
TH
Amplify Weight Loss Drug & Treatment ETF
THNR
Volume
663
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
TH
THNR
TH
Amplify Weight Loss Drug & Treatment ETF
THNR
News
·
Lilly vs. Novo: Inside the Milan EASD Showdown and the ETFs Poised to Win
AUM
N/A
Volume
663
Yield
1.69%
Chart
Earnings
News
About
Dividends
Insider
Filings
Lilly vs. Novo: Inside the Milan EASD Showdown and the ETFs Poised to Win
At the 2026 EASD conference in Milan, Eli Lilly and Novo Nordisk presented competing clinical data in the weight-loss drug market. Lilly's retatrutide showed 34.9% of patients lost at least 25% of body weight, while Novo countered with cardiovascular safety data for Ozempic. The GLP-1 market is expanding rapidly with over 27% of global adults eligible for these medications, attracting competition from Pfizer, Amgen, and Regeneron. Healthcare ETFs like OZEM, HRTS, and THNR offer diversified exposure to this growing sector.
Zacks Investment Research · Oct 1, 2026
Can Eli Lilly ETFs Surge on Approval of Alzheimer's Drug?
On Jun 10, the FDA's Peripheral and Central Nervous System Drugs Advisory Committee (PCNS) voted 11-0, unanimously recommending the approval of Eli Lilly's (LLY) Alzheimer's disease drug, donanemab.
Zacks Investment Research · Jun 19, 2024
ETFs Bet High On Weight Loss Drugs, But Industry Observers Question Long-Term Potential
With more than 10% of the global population now suffering from obesity, the share prices of companies providing the latest weight-loss drugs have surged. However, according to industry observers, investors considering exposure through the newly launched weight-loss exchange-traded funds (ETFs) need to evaluate their potential. The Roundhill GLP-1 Weight Loss ETF (NASDAQ:OZEM) and the Amplify Weight Loss Drug and Treatment ETF (NYSE:THNR) debuted on May 21 with an expense ratio of 0.59%. Both ETFs have significant weightings in industry giants Eli Lilly And Co (NYSE:LLY) and Novo Nordisk A/S (NYSE:NVO), with OZEM and THNR allocating about 40% and 30%, respectively, to these companies. Eli Lilly and ...Full story available on Benzinga.com
Benzinga · Jun 7, 2024
ETFs to Profit from the Weight Loss Drug Boom
The market for GLP-1 drugs could soar to $130 billion by 2030
Zacks Investment Research · Jun 4, 2024
Holdings
Open Orders (0)
Positions (0)
Order History
Dividends
Transfers
Log In
to start trading
TH
THNR
Amplify Weight Loss Drug & Treatment ETF
Buy
Sell
Market
Limit
Soon
THNR
25%
50%
75%
Max
Pay with
—
Start Trading
Available Balance
0.00
Your Position
You don't own any THNR yet.
Related Tickers
Earnings
Dividends
Last · Dec 30
Annual
Amount
$0.41
Yield
1.69%
Annual
$0.41